Chiltern release Medidata Rave Value Accelerators for capturing, managing and reporting clinical research data

Published: 13-Jun-2017
Regulatory Analysis

Chiltern announced the release of the Medidata Rave Value Accelerators, tools that streamline the clinical trial process and help trial sponsors cut the time, cost and effort of bringing a new device to market

The tools function in any type of study requirement — from simple to complex — out of the box or customised to the customer’s process.

The customer can select which tools are appropriate for their needs and the tools can also be used anytime, anywhere, and by multiple users during the setup and conduct of the trial.

Mark Penniston, Executive Vice President, Clinical Analytics and General Manager at Chiltern, said: “Our partnership with Medidata and its industry-leading platform aligns with our strategy providing an exceptional customer experience around best-in-class technologies.

"Currently our Data & Analysis team leads the field in providing the latest platforms and technologies and the Medidata Rave Value Accelerators support our stronghold in the technology space.”

Included are three accelerator tools: the Chiltern EC Reviewer for Medidata Rave, Chiltern EC Detector for Medidata Rave and Chiltern EC Analyzer for Medidata Rave.

The accelerator tools are designed to create flexibility for users, helping them accommodate their workflow environments, and are scalable from one study to hundreds and from Phase I to global Phase IV studies.

  • Companies:
  • Chiltern International
See more

You may also like

Training & Education

Chiltern presents webinar on imaging diagnostics and theranostics

Read more
“Imaging Diagnostics and Theranostics: Meeting Clinical Development Challenges” webinar will take place on May 17 at 10am EDT

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  3. Overcoming CMC challenges in cell and gene therapy: part II Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  4. Edward Rayner appointed as as Non-Executive Director of Sphere Fluidics Ed’s appointment will strengthen the company’s strategic vision as it progresses ambitious plans for future growth and commercial success
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Meeting new USP Chapter 41 requirements Balances are the essential means by which all therapeutics are ultimately supplied in safe dosages. Dirk Ahlbrecht, Sartorius Group, looks at how to ensure measurements are both accurate and up to new USP standards

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Training & Education

Chiltern presents webinar on imaging diagnostics and theranostics

“Imaging Diagnostics and Theranostics: Meeting Clinical Development Challenges” webinar will take place on May 17 at 10am EDT
Regulatory

New FDA binding guidelines force industry switch to digital

From December 2017, the FDA will require all NGA licence applications to be submitted electronically – part of a push towards a digital data pharma industry
Regulatory

Chiltern acquires Ockham

Contract research organisations merge their operations
Research & Development

New automated tissue dissociation systems

Introducing the new Singulator series (100 and 200)
Regulatory

Overcoming CMC challenges in cell and gene therapy: part II

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Subscribe now